Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study.
Thyroid neoplasm
low-risk papillary thyroid carcinomas
lymphatic vascular invasion
lymphovascular invasion
risk adjustment
venous vascular invasion
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
28 Aug 2023
28 Aug 2023
Historique:
received:
30
05
2023
accepted:
26
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
aheadofprint
Résumé
Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown. The aim of this study was to evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs. Retrospective study including patients with otherwise low-risk PTCs but with vascular invasion, diagnosed between 2013 and 2019. The persistence/recurrence during the follow-up was evaluated. Pathology was reviewed to confirm the presence of lymphovascular invasion and determine the type of invasion. A total of 141 patients were included. Lymphovascular invasion was confirmed in 20.6%. After surgery, 48.9% (N = 69) of the patients received radioactive iodine (RAI). The median follow-up time was 4 [3-6] years. Overall, 6 (4.2%) patients experienced persistent/recurrent disease in the neck, including 3 with lymphovascular invasion, confirmed as "only lymphatic". Overall, patients with tumors harboring lymphovascular invasion had sensibly more persistent/recurrence disease compared with those without lymphovascular invasion (10.3% vs 2.7%, p = 0.1), especially in the subgroup of patients not treated with RAI (20% vs 1.6%, p = 0.049) [OR 15.25, 95% CI 1.24-187.85, p = 0.033]. Lymphovascular invasion, including lymphatic invasion only, is associated with a sensibly higher risk of persistent/recurrent disease in otherwise low-risk PTCs, namely in patients not treated with RAI. Lymphatic invasion could have a role in risk-stratification systems for decision making.
Identifiants
pubmed: 37639174
doi: 10.1007/s12020-023-03475-8
pii: 10.1007/s12020-023-03475-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
L. Davies, H.G. Welch, Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head. Neck Surg. 140, 317 (2014)
doi: 10.1001/jamaoto.2014.1
pubmed: 24557566
J.P. Brito, A. Al Nofal, V.M. Montori, I.D. Hay, J.C. Morris, The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in olmsted county, minnesota during 1935 Through 2012. Thyroid 25, 999–1007 (2015)
doi: 10.1089/thy.2014.0594
pubmed: 26103159
pmcid: 4560845
B. Aschebrook-Kilfoy, M.H. Ward, M.M. Sabra, S.S. Devesa, Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 21, 125–134 (2011)
doi: 10.1089/thy.2010.0021
pubmed: 21186939
pmcid: 3025182
L. Leenhardt, M.O. Bernier, M.H. Boin-Pineau, B. Conte Devolx, R. Maréchaud, P. Niccoli-Sire, M. Nocaudie, J. Orgiazzi, M. Schlumberger, J.L. Wémeau, L. Chérie-Challine, F. De Vathaire, Advances in diagnostic practices affect thyroid cancer incidence in France. Eur. J. Endocrino. 133–139 (2004).
S. Vaccarella, S. Franceschi, F. Bray, C.P. Wild, M. Plummer, Dal, L. Maso, Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375, 614–617 (2016)
doi: 10.1056/NEJMp1604412
pubmed: 27532827
B.C. James, J.M. Mitchell, H.D. Jeon, N. Vasilottos, R.H. Grogan, B. Aschebrook-Kilfoy, An update in international trends in incidence rates of thyroid cancer, 1973–2007. Cancer Causes Control 29, 465–473 (2018)
doi: 10.1007/s10552-018-1023-2
pubmed: 29623496
A. Maniakas, L. Davies, M.E. Zafereo, Thyroid disease around the World. Otolaryngologic Clin. North Am. 51, 631–642 (2018)
doi: 10.1016/j.otc.2018.01.014
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
L. Falvo, A. Catania, V. D’Andrea, A. Marzullo, M.C. Giustiniani, E. De Antoni, Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann. Surg. 241, 640–646 (2005)
doi: 10.1097/01.sla.0000157317.60536.08
pubmed: 15798466
pmcid: 1357068
R.E. Gardner, R.M. Tuttle, K.D. Burman, S. Haddady, C. Truman, Y.H. Sparling, L. Wartofsky, R.B. Sessions, M.D. Ringel, Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch. Otolaryngol. Head. Neck Surg. 126, 309 (2000)
doi: 10.1001/archotol.126.3.309
pubmed: 10722002
O. Mete, S.L. Asa, Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod. Pathol. 24, 1545–1552 (2011)
doi: 10.1038/modpathol.2011.119
pubmed: 21804527
T. Nishida, S. Katayama, M. Tsujimoto, The clinicopathological significance of histologic vascular invasion in differentiated thyroid carcinoma. Am. J. Surg. 183, 80–86 (2002).
doi: 10.1016/S0002-9610(01)00843-1
pubmed: 11869709
L.A. Akslen, A.O. Myking, H. Salvesen, J.E. Varhaug, Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. Eur. J. Cancer 29, 44–51 (1993)
doi: 10.1016/0959-8049(93)90574-Y
W.J. Simpson, S.E. McKinney, J.S. Carruthers, M.K. Gospodarowicz, S.B. Sutcliffe, T. Panzarella, Papillary and follicular thyroid cancer. Am. J. Med. 83, 479–488 (1987)
doi: 10.1016/0002-9343(87)90758-3
pubmed: 3661584
K.T. Mai, P. Khanna, H.M. Yazdi, D.G. Perkins, J.P. Veinot, J. Thomas, M. Lamba, B.D. Nair, Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma. Pathology 34(3), 239–244 (2002)
doi: 10.1080/00313020220131291
pubmed: 12109784
J.C. Furlan, Y.C. Bedard, I.B. Rosen, Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas1. J. Am. Coll. Surg. 198, 341–348 (2004)
doi: 10.1016/j.jamcollsurg.2003.11.012
pubmed: 14992733
L. Lamartina, S. Bidault, J. Hadoux, J. Guerlain, E. Girard, I. Breuskin, M. Attard, V. Suciu, E. Baudin, A. Al Ghuzlan, S. Leboulleux, D. Hartl, Can preoperative ultrasound predict extrathyroidal extension of differentiated thyroid cancer? Eur. J. Endocrinol. 185, 13–22 (2021)
doi: 10.1530/EJE-21-0091
pubmed: 33886499
S. Bidault, E. Girard, M. Attard, G. Garcia, J. Guerlain, I. Breuskin, E. Baudin, J. Hadoux, C. Garcia, L. Lamartina, D.M. Hartl, Preoperative ultrasound mapping of the vagus nerve in thyroid surgery. Gland Surg. 11, 91–99 (2022)
doi: 10.21037/gs-21-580
pubmed: 35242672
pmcid: 8825509
O. Mete, R.R. Seethala, S.L. Asa, M.J. Bullock, S.E. Carty, S.P. Hodak, J.B. McHugh, Y.E. Nikiforov, J. Pettus, M.S. Richardson, J. Shah, L.D.R. Thompson, College of American Pathologists: Protocol for the Examination of Specimens From Patients With Carcinomas of the Thyroid Gland. (2019). https://documents.cap.org/protocols/cp-endocrine-thyroid-19-4200.pdf
C. Wittekind, TNM Klassifikation maligner Tumoren. (Springer, Berlin, 2020)
L. Lamartina, D. Handkiewicz-Junak, Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission? Eur. J. Endocrinol. 182, D1–D16 (2020)
doi: 10.1530/EJE-19-0960
pubmed: 32197235
C. Durante, T. Montesano, M. Torlontano, M. Attard, F. Monzani, S. Tumino, G. Costante, D. Meringolo, R. Bruno, F. Trulli, M. Massa, A. Maniglia, R. D'Apollo, L. Giacomelli, G. Ronga, S. Filetti; PTC Study Group, Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J. Clin. Endocrinol. Metab. 98, 636–642 (2013)
doi: 10.1210/jc.2012-3401
pubmed: 23293334
G. Grani, L. Lamartina, C. Durante, S. Filetti, D.S. Cooper, Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol. 6, 500–514 (2018)
doi: 10.1016/S2213-8587(17)30325-X
pubmed: 29102432
S. Hescot, H. Sheikh-Alard, M. Kordahi, D. Hartl, J. Hadoux, M. Terroir, I. Breuskin, E. Baudin, J.Y. Scoazec, M. Schlumberger, A. Al Ghuzlan, S. Leboulleux, Impact of expert review of histological diagnosis of papillary and follicular thyroid cancer. Endocrine 72, 791–797 (2021)
doi: 10.1007/s12020-020-02531-x
pubmed: 33128670